Novartis AG (NVSN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Novartis AG (NVSN) has a cash flow conversion efficiency ratio of 0.094x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (MX$3.68 Billion ≈ $211.55 Million USD) by net assets (MX$38.93 Billion ≈ $2.24 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Novartis AG defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Novartis AG - Cash Flow Conversion Efficiency Trend (2014–2025)
This chart illustrates how Novartis AG's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Novartis AG Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Novartis AG ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Philip Morris International Inc
NYSE:PM
|
0.055x |
|
Contemporary Amperex Technology Co Ltd Class A
SHE:300750
|
0.133x |
|
Novartis AG ADR
NYSE:NVS
|
0.094x |
|
AstraZeneca PLC
NASDAQ:AZN
|
0.071x |
|
Royal Bank of Canada
TO:RY
|
-0.106x |
|
LVMH Moët Hennessy - Louis Vuitton Société Européenne
PA:MC
|
0.118x |
|
GE Vernova LLC
NYSE:GEV
|
0.344x |
|
PetroChina Co Ltd Class A
SHG:601857
|
0.068x |
Annual Cash Flow Conversion Efficiency for Novartis AG (2014–2025)
The table below shows the annual cash flow conversion efficiency of Novartis AG from 2014 to 2025. For the full company profile with market capitalisation and key ratios, see Novartis AG market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | MX$46.55 Billion ≈ $2.68 Billion |
MX$19.14 Billion ≈ $1.10 Billion |
0.411x | +3.00% |
| 2024-12-31 | MX$44.13 Billion ≈ $2.54 Billion |
MX$17.62 Billion ≈ $1.01 Billion |
0.399x | +16.51% |
| 2023-12-31 | MX$46.75 Billion ≈ $2.69 Billion |
MX$16.02 Billion ≈ $922.07 Million |
0.343x | +43.05% |
| 2022-12-31 | MX$59.42 Billion ≈ $3.42 Billion |
MX$14.24 Billion ≈ $819.29 Million |
0.240x | +7.81% |
| 2021-12-31 | MX$67.82 Billion ≈ $3.90 Billion |
MX$15.07 Billion ≈ $867.34 Million |
0.222x | -7.75% |
| 2020-12-31 | MX$56.67 Billion ≈ $3.26 Billion |
MX$13.65 Billion ≈ $785.56 Million |
0.241x | -1.79% |
| 2019-12-31 | MX$55.55 Billion ≈ $3.20 Billion |
MX$13.62 Billion ≈ $784.12 Million |
0.245x | +35.24% |
| 2018-12-31 | MX$78.69 Billion ≈ $4.53 Billion |
MX$14.27 Billion ≈ $821.36 Million |
0.181x | +6.67% |
| 2017-12-31 | MX$74.23 Billion ≈ $4.27 Billion |
MX$12.62 Billion ≈ $726.34 Million |
0.170x | +10.97% |
| 2016-12-31 | MX$74.89 Billion ≈ $4.31 Billion |
MX$11.47 Billion ≈ $660.39 Million |
0.153x | -0.67% |
| 2015-12-31 | MX$77.12 Billion ≈ $4.44 Billion |
MX$11.90 Billion ≈ $684.68 Million |
0.154x | -21.36% |
| 2014-12-31 | MX$70.84 Billion ≈ $4.08 Billion |
MX$13.90 Billion ≈ $799.78 Million |
0.196x | -- |
About Novartis AG
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic … Read more